Claims for Patent: 8,513,210
✉ Email this page to a colleague
Summary for Patent: 8,513,210
Title: | Prostate cancer vaccine |
Abstract: | Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines. |
Inventor(s): | McNeel; Douglas G. (Madison, WI), Olson; Brian M. (Madison, WI) |
Assignee: | Wisconsin Alumni Research Foundation (Madison, WI) |
Application Number: | 13/031,396 |
Patent Claims: | 1. A DNA vaccine comprising a plasmid vector comprising a polynucleotide operatively linked to a transcriptional regulatory element wherein the polynucleotide encodes a member
selected from (i) fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain defined by SEQ ID NO:9, (ii) a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain defined by SEQ ID
NO:10, (iii) a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain defined by SEQ ID NO:11, and (iv) a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain defined by SEQ
ID NO:12, wherein upon administration of said vaccine to a mammal a cytotoxic immune reaction against cells expressing androgen receptor is induced.
2. The DNA vaccine of claim 1, wherein the plasmid vector comprises (a) a backbone of pNGVL3; (b) a polynucleotide operably inserted therein wherein the polynucleotide encodes a member selected from (i) a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain defined by SEQ ID NO:9, (ii) a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain defined by SEQ ID NO:10, (iii) a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain defined by SEQ ID NO:11, and (iv) a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain defined by SEQ ID NO:12; and optionally (c) an immunostimulatory sequence (ISS) motif. 3. The DNA vaccine of claim 1, wherein the plasmid vector comprises (a) a polynucleotide operatively linked to a CMV promoter wherein the polynucleotide encodes a member selected from (i) a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain defined by SEQ ID NO:9, (ii) a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain defined by SEQ ID NO:10, (iii) a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain defined by SEQ ID NO:11, and (iv) a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain defined by SEQ ID NO:12; (b) a CMV intron A operatively linked to the polynucleotide for enhancing expression of the polynucleotide; and optionally (c) at least one copy of an immunostimulatory fragment comprising 5'-GTCGTT-3'. 4. A pharmaceutical composition comprising the DNA vaccine of claim 1, and a pharmaceutically acceptable carrier. 5. A pharmaceutical composition comprising the DNA vaccine of claim 1, further comprising a suitable amount of GM-CSF. 6. The DNA vaccine of claim 1, wherein the fragment of a mammalian androgen receptor is a fragment of a human androgen receptor. 7. A DNA vaccine comprising a plasmid vector comprising a polynucleotide operatively linked to a transcriptional regulatory element wherein the polynucleotide encodes a fragment of a human androgen receptor ligand binding domain consisting essentially of a fragment of SEQ ID NO:2 starting from a position ranging from amino acid 761 to amino acid 770 of SEQ ID NO:2 and ending at a position ranging from amino acid 859 to amino acid 867 of SEQ ID NO:2. |
Details for Patent 8,513,210
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2026-09-01 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2026-09-01 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2026-09-01 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.